Spread the love“`html 1. Understanding JavaScript Loading JavaScript is a key component of modern web development, enabling interactive features and functionalities that enhance user experience.
ATTR-cardiac amyloidosis (ATTR-CM) is a progressive heart condition often mistaken for normal aging. For years, communication in the category has focused on urgency and decline, leaving patients with ...
BridgeBio Pharma currently markets the ATTR-CM treatment Attruby, which has been on a strong sales trajectory since its 2024 approval. (iStock/Getty Images Plus) BridgeBio Pharma is teaming up with ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults. The American Heart Association's ...
Kevin M. Alexander, MD, reflects on ACC data for ATTR-CM and its implications for patient care, stressing that clinical trials and extension analyses show ATTR therapies extend survival, improve ...
In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...
Based on market patterns in other diseases such as pulmonary arterial hypertension and atrial fibrillation, Alnylam believes that the entire ATTR-CM category is still in its infancy. (iStock / Getty ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier ...
His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...
Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival. In ‘Evaluating Transthyretin Stabilizers and Silencers ...
Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety. This episode, titled ‘Key Efficacy and Safety ...
Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results